Abstract
Purpose. To compare three liver models (well-stirred, parallel tube, and dispersion) for the prediction of in vivo intrinsic clearance (CLint), hepatic clearance (CLh), and hepatic availability (Fh) of a wide range of drugs in the rat using in vitro data from two in vitro sources.
Methods. In vitro CLint was obtained from studies using isolated rat hepatocytes (35 drugs) or rat liver microsomes (52 drugs) and used to predict in vivo CLint using reported scaling factors, and subsequently CLh and Fh were predicted based on the three liver models. In addition, in vivo CLint values were calculated from the reported values of CLh based on each of the three models.
Results. For all of the parameters, predictions from hepatocyte data were consistently more accurate than those from microsomal data. Comparison of in vitro and in vivo CLint values demonstrated that the dispersion model and the parallel tube model were comparable and more accurate (less bias, more precise) than the well-stirred model. For CLh and Fh prediction, the three models performed similarly.
Conclusions. Considering the statistics of the predictions for three liver models, the use of parallel tube model is recommended for the evaluation of in vitro CLint values both from microsomes and hepatocytes. However, for the prediction of the in vivo drug (hepatic) clearance from in vitro data, as there are minimal differences between the models, the use of the well-stirred liver model is recommended.
Similar content being viewed by others
references
J. H. Lin and A. Y. Lu. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 49:403–449 (1997).
R. S. Obach. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27:1350–1359 (1999).
J. B. Houston and D. J. Carlile. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab. Rev. 29:891–922 (1997).
M. Roberts and M. Rowland. Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J. Pharm. Pharmacol. 38:177–181 (1986).
Y. Sugiyama, Y. Sawada, T. Iga, and M. Hanano. Reconstruction of in vivo metabolism from in vitro data. In R. Kato, R. W. Estabrook, and M. N. Cayen (eds.), Xenobiotic Metabolism & Disposition; Proceedings of the 2nd International ISSX Meeting, Taylor & Francis, London, 1989, pp. 225–235.
J. B. Houston. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1469–1479 (1994).
T. Lave, S. Dupin, C. Schmitt, R. C. Chou, D. Jaeck, and P. Coassolo. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J. Pharm. Sci. 86:584–590 (1997).
Y. Naritomi, S. Terashita, S. Kimura, A. Suzuki, A. Kagayama, and Y. Sugiyama. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 29:1316–1324 (2001).
M. Chiba, M. Hensleigh, and J. H. Lin. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem. Pharmacol. 53:1187–1195 (1997).
J. H. Lin, M. Chiba, S. K. Balani, I.-W. Chen, G. Y.-S. Kwei, K. J. Vastag, and J. A. Nishime. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:1111–1120 (1996).
T. Prueksaritanont, S. K. Balani, L. M. Dwyer, J. D. Ellis, L. R. Kauffman, S. L. Varga, S. M. Pitzenberger, and A. D. Theoharides. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372: In vivo and in vitro studies in rats, dogs, monkeys, and humans. Drug Metab. Dispos. 23:688–695 (1995).
R. Ishida, S. Obara, Y. Masubuchi, S. Narimatsu, S. Fujita, and T. Suziki. Induction of propranolol metabolism by the azo dye sudan III in rats. Biochem. Pharmacol. 43:2489–2492 (1992).
D. B. Jones, M. S. Ching, R. A. Smallwood, and D. J. Morgan. A carrier-protein receptor is not a prerequisite for avid hepatic elimination of highly bound compounds: A study of propranolol elimination by the isolated perfused rat liver. Hepatology 5:590–593 (1985).
T. Iwatsubo, H. Suzuki, and Y. Sugiyama. Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. J. Pharmacol. Exp. Ther. 283:462–469 (1997).
L. E. Witherow and J. B. Houston. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J. Pharmacol. Exp. Ther. 290:58–65 (1999).
A. J. Stevens, S. W. Martin, B. S. Brennan, A. McLachlan, L. A. Gifford, M. Rowland, and J. B. Houston. Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. Pharm. Res. 12:1987–1996 (1995).
D. Matthew, B. Brennan, K. Zomorodi, and J. B. Houston. Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. Pharm. Res. 10:418–422 (1993).
D. J. Carlile, K. Zomorodi, and J. B. Houston. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab. Dispos. 25:903–911 (1997).
D. J. Carlile, N. Hakooz, and J. B. Houston. Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity. Drug Metab. Dispos. 27:526–532 (1999).
G. M. Pollack, K. L. R. Brouwer, K. B. Demby, and J. A. Jones. Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green or galactose. Drug Metab. Dispos. 18:197–202 (1999).
K. S. Pang and J. R. Gillette. Compications in the estimation of hepatic blood flow in vivo by pharmacokinetic parameters. Drug Metab. Dispos. 6:567–576 (1978).
R. S. Obach, J. G. Baxter, T. E. Liston, B. M. Silber, B. C. Jones, F. MacIntyre, D. J. Rance, and P. Wastall. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283:46–58 (1997).
L. B. Sheiner and S. L. Beal. Some suggestions for measuring predictive performance. J. Pharmacokin. Biopharm. 9:503–512 (1981).
S. Miyauchi, Y. Sawada, T. Iga, M. Hanano, and Y. Sugiyama. Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. Pharm. Res. 10:434–440 (1993).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ito, K., Houston, J.B. Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes. Pharm Res 21, 785–792 (2004). https://doi.org/10.1023/B:PHAM.0000026429.12114.7d
Issue Date:
DOI: https://doi.org/10.1023/B:PHAM.0000026429.12114.7d